BioCatalyst

NAMS — NewAmsterdam Pharma Co N.V. catalysts

2 verified catalyst event(s) for NewAmsterdam Pharma Co N.V. (ticker NAMS). Each is linked to its official source. Verified as of 2026-09-20.

Next verified catalyst

2026-11-01 — Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardio · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-11 (month)
in 1mo
ESTIMATED
 READOUT
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients W
Phase 3 · Atherosclerotic Cardiovascular Disease
 NAMS NewAmsterdam Pharma Co N.V. Obicetrapib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
 READOUT
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Phase 2 · Dyslipidemias
 NAMS NewAmsterdam Pharma Co N.V. obicetrapib 10 mg + obicetrapib/evolocum ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.